

CURRICULUM VITAE

Name and surname: Giancarlo Silvio Mareni

Place of birth: Milan (Italy)

Date of birth: February 11, 1958.

Marital status: married to Mrs. Daniela Cardinale. Two children: Elena and Valeria

Institute: Centro Cardiologico Monzino, IRCCS, Institute of Cardiology of the University of Milan.

Phone: +39.02.58002582; Fax: +39.02.58002287; e-mail: giancarlo.mareni@ccfm.it

Residence: Via Fratelli Cervi, Residenza Sorgente 8, 20090 Segrate (Milan), Italy. Phone: +39.02.2151171.

Current position:

Director, Intensive Cardiac Care Unit, Centro Cardiologico Monzino, IRCCS, Institute of Cardiology of the University of Milan.

Studies:

- 1977: Scientific school certificate
- 1983: degree in Medicine and Surgery at the University of Milan (110/110 cum laude). Thesis title: "Cardiac rhythm evaluated by Holter monitoring in hypertension". Supervisor: Prof. Maurizio D. Guazzi.
- 1984: Qualification to practice the profession as a medical doctor
- 1985: Specialized in Cardiology at the University of Milan (70/70 cum laude).
- 1990: Specialized in Internal Medicine at the University of Milan (58/70)

Professional curriculum:

1978-1980: Internal student at the Pathologic Anatomy Institute, Niguarda Hospital

1980-1982: Internal student at the Internal Medicine Department, Niguarda Hospital

1982-1985: Internal student at the Institute of Cardiology, University of Milan

1985-1986: Assistant Cardiologist (full time) at the Centro Cardiologico Monzino, Institute of Cardiology, University of Milan

1987-1989: Assistant Cardiologist (full time) at the “Città di Milano” Hospital

1988-1989: Military service

1989-1996: Assistant Cardiologist (full time) at the Centro Cardiologico Monzino, Institute of Cardiology, University of Milan

1996-1999: Deputy Director Cardiologist (full time) at the Centro Cardiologico Monzino, Institute of Cardiology, University of Milan

2000-present: Director of the Intensive Cardiac Care Unit (full time) at the Centro Cardiologico Monzino, Institute of Cardiology, University of Milan

2009-present: Adjunct Professor of Cardiology, at the Faculty of Medicine and Surgery, of the University of Milan, Italy.

2008-present: Tutor at the Specialisation School of Cardiology at the University of Milan, Italy

SCIENTIFIC SOCIETY MEMBERSHIPS:

Italian Society of Cardiology (SIC),

National Association of Hospital Cardiology Practitioners (ANMCO),

Vice-president (2017-2020) of the Italian Society of Nephro-Cardiology (SINCAR)

International Society of Cardio-Oncology,

Fellow of the European Society of Cardiology (FESC),

Member of the Working Group on Acute Cardiac Care of the European Society of Cardiology (WG27)

Reviewer for high ranking medical journals including:

New England Journal of Medicine;

JAMA,

Journal of the American College of Cardiology,

Circulation

American Heart Journal

American Journal of Cardiology

European Heart Journal

European Journal of Heart Failure

International Journal of Cardiology,

Critical Care Medicine,

Swiss Medical Weekly,

Kidney International,

American Journal of Medicine

Medicine

Catheterization and Cardiovascular Interventions,

Eurointervention

Nature Clinical Practice Nephrology,

Nephrology and Dialysis Transplantation,

Therapy,

Hemodialysis International
Clinical Biochemistry,
American Journal of Kidney Disease,
Nature Reviews Nephrology,
Biomarkers,
Internal Medicine Journal
International Journal of Vascular Medicine
PlosOne
Cardiorenal Medicine
Critical Care
Herz

Principal Investigator in profit clinical trials:

GUSTO-IV
APPRAISE-2
CHAMPION-PCI
EARLY-ACS
EPICOR
OASIS-6
RE-DEEM
SEPIA-ACS1-TIMI 42
TRA 2p-TIMI 50
VISTA-16
PEGASUS-TIMI 54
IMPROVE-IT
FOURIER
TIGRIS
TRYTON
SMILE IV
CHIARA-MIA 2
FOURIER-OLE
PARADISE-MI
SECURE

COURSE GIVEN (2010-2017)

2012: Acute coronary syndromes in ICCU
2013: Renal replacement therapies use in cardiovascular disease
2014: UTIC Culture ACS
2016: Use of levosimendan in the cardiac setting (for Polish Doctors)

INTERNATIONAL COLLABORATIONS

Prof. Christian Mueller (Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Basel, Switzerland)

Prof. Richard Solomon (Nephrology - Burlington, VT, The UVM Medical Center; USA)

Hariprasad Trivedi (Division of Nephrology and Kidney Disease Center, Medical College of Wisconsin, Milwaukee; USA)

Ulf Nyman (Department of Radiology, Lasarettet Trelleborg, University of Lund, Trelleborg, Sweden)

Prof. Amir Kazory (Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida, USA).

Costanzo Maria Rosa, M.D., (Advocate Heart Institute, Naperville, Illinois; USA)

Piero Pollesello P, M.D. Critical Care Proprietary Products, Orion Pharma, Espoo, Finland

Prof. Alexandre Mebazaa (Department of Anaesthesia and Burn and Critical Care, Saint-Louis-Lariboisière Hospital, AP-HP, University Paris-Diderot, Paris, France)

MEMBER OF THE EDITORIAL BOARD OF INTERNATIONAL JOURNALS

Journal of Nephrology,

World Journal of Cardiology,

World Journal of Nephrology,

Cardiology and Cardiovascular Medicine

Journal of Heart and Stroke

LIST OF PUBLICATIONS

H-index: 34 (SCOPUS)

Original articles on international journals.

1. P.Della Bella, C.Cipolla, F.Doni, S.Grazi, G.Marenzi, A.Rimondini, A.Salvioni, C.Tondo, MD.Guazzi. Intravenous disopyramide facilitates termination of atrial flutter with overdrive pacing. In Santini, Pistolese, Alliegro editors: Progress in Clinical Pacing 1986; pag.442-444.
2. P.Della Bella, C.Tondo, G.Marenzi, CM.Cipolla, F.Doni, S.Grazi, A.Rimondini, A.Salvioni, MD.Guazzi. Facilitating influence of disopyramide on atrial flutter termination by overdrive pacing. Am J Cardiol 1988;61:1046-1049.
3. P.Della Bella, G.Marenzi, C.Tondo, F.Doni, G.Lauri, S.Grazi, MD.Guazzi. Effects of disopyramide on cycle length, effective refractory period and excitable gap of atrial flutter, and relation to arrhythmia termination by overdrive pacing. Am J Cardiol 1989;63:812-816.
4. P.Della Bella, C.Tondo, G.Marenzi, S. Grazi. Polimorphous ventricular tachycardia as undesirable effect of the association of quinidine treatment with hysteresis ventricular inhibited pacing. Eur Heart J 1990;11:1124-1126.
5. P.Della Bella, G.Marenzi, C.Tondo, D.Cardinale, F.Giraldi, G.Lauri, M.Guazzi. Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. Am J Cardiol 1991;68:492-497.
6. G.Marenzi, S.Grazi, F.Giraldi, G.Lauri, G.Perego, M.Guazzi, A.Salvioni, MD.Guazzi. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med 1993;94:49-56.
7. PG.Agostoni, G.Marenzi, M.Pepi, E.Doria, A.Salvioni, G.Perego, G.Lauri, F.Giraldi, S.Grazi, MD.Guazzi. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol 1993;21:424-431.
8. M.Pepi, G.Marenzi, PG.Agostoni, E.Doria, P.Barbier, M.Muratori, F.Celeste, MD.Guazzi. Sustained cardiac diastolic changes elicited by ultrafiltration in patients with moderate congestive heart failure: pathophysiological correlates. Br Heart J 1993;70:135-140.
9. PG.Agostoni, G.Marenzi, G.Lauri, G.Perego, M.Schianni, P.Sganzerla, MD.Guazzi. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 1994;96:191-199.
10. A.Salvioni, G.Marenzi, PG.Agostoni, S.Grazi, MD.Guazzi. Influence of heparin on fibrinogen and D-Dimer plasma levels in acute myocardial infarction treated with streptokinase. Eur Heart J 1994;15:654-659.
11. A. Salvioni, G.Marenzi, G.Lauri, F.Giraldi, GB.Perego, S.Grazi, MD.Guazzi. Beta-Thromboglobulin plasma levels in the first week after myocardial infarction: influence of thrombolytic therapy. Am Heart J 1994;128:472-476.
12. Guazzi MD, Agostoni PG, Perego GB, Lauri G, Guazzi M, Salvioni A, Giraldi F, Matturri M, Guazzi M, Marenzi G. The apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 1994; 72:534-539.

13. G.Marenzi, G.Lauri, M.Guazzi, GB.Perego, PG.Agostoni. Ultrafiltration in moderate heart failure: exercise oxygen uptake as a predictor of the clinical benefit. *Chest* 1995; 108:94-98.
14. PG.Agostoni, G.Marenzi, P.Sganzerla, E.Assanelli, M.Guazzi, GB.Perego, G.Lauri, E.Doria, M.Pepi, MD.Guazzi. Lung-heart interaction as a substrate for the improvement in exercise capacity following body fluid volume depletion in moderate congestive heart failure. *Am J Cardiol* 1995; 76:793-798.
15. M.Guazzi, G.Marenzi, E.Assanelli, GB.Perego, G.Cattadori, E.Doria, PG.Agostoni. Evaluation of the dead space/tidal volume ratio in patients with chronic congestive heart failure. *J Cardiac Failure* 1995; Vol.1 (5):1-8.
16. A.Salvioni, GB.Perego, G.Marenzi, G.Lauri, F.Giraldi, S.Grazi, MD.Guazzi. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate. *Eur Heart J* 1996;17:230-236.
17. GB.Perego, G.Marenzi, M.Guazzi, P.Sganzerla, E.Assanelli, P.Palermo, B.Conconi, G.Lauri, PG.Agostoni. Contribution of Po₂, P50, and Hb to changes in arteriovenous O₂ content during exercise in heart failure. *J Appl Physiol*. 1996; 80(2): 623-31.
18. P.Agostoni, G.Marenzi, M.Guazzi, MD.Guazzi. Influence of ACE inhibition on fluid metabolism in chronic heart failure and its pathophysiologic relevance. *J Cardiovasc Pharmacol Therapeut* 1996; 1(4):279-286.
19. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni PG. Improvement of alveolar-capillary diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. *Circulation* 1997;7:1930-36.
20. PG.Agostoni, K.Wasserman, GB.Perego, G.Marenzi, M.Guazzi, E.Assanelli, G.Lauri, MD.Guazzi. Oxygen transport to muscle during exercise in chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy. *Am J Cardiol* 1997;79:29-33.
21. A.Salvioni, S.Galli, G.Marenzi, G.Lauri, GB.Perego, E.Assanelli, MD.Guazzi. Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty. *Am Heart J* 1998;135:
22. A.Salvioni, GB.Perego, G.Marenzi, S.Galli, E.Assanelli, MD.Guazzi. Platelet activity in the early stage of acute myocardial infarction: relation to time of presentation, treatment with either tissue plasminogen activator or streptokinase and cyclooxygenase inhibition. *J Thrombosis and Thrombolysis* 1998;5:65-71.
23. PG.Agostoni, K.Wasserman, M.Guazzi, G.Cattadori, P.Palermo, G.Marenzi, MD.Guazzi. Exercise-induced hemoconcentration in heart failure due to dilated cardiomyopathy. *Am J Cardiol* 1999, 83:278-280.
24. M.Pepi, PG.Agostoni, G.Marenzi, E.Doria, M.Guazzi, G.Lauri, A.Maltagliati, M.Guazzi. The influence of diastolic and systolic function on exercise performance in heart failure due to dilated cardiomyopathy or ischemic heart disease. *Eur J Heart Failure* 1999;1:161-167.
25. Guazzi M., Melzi G., Marenzi G., Agostoni P. Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. *Clin Pharmacol Ther* 1999;65(3):319-327.

26. Agostoni PG, Wasserman K, Perego GB, Guazzi M, Cattadori G, Palermo P, Lauri G, Marenzi G. Non-invasive measurement of stroke volume during exercise in heart failure patients. *Clin Sci* 2000;98(5):545-551.
27. Marenzi G, Agostoni P, Guazzi M, Lauri G, Assanelli E, Guazzi MD. The noradrenaline plasma concentration and its gradient across the lung. *Eur J Clin Invest* 2000, 30(8):660-667.
28. Agostoni P, Cattadori G, Guazzi M, Palermo P, Bussotti M, Marenzi G. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. *Am Heart J* 2000;140 (5):e24.
29. Agostoni P, Cattadori G, Guazzi M, Bussotti M, Conca C, Lomanto M, Marenzi G, Guazzi MD. Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. *Am J Med* 2000; 109:450-5.
30. Agostoni PG, Guazzi M, Bussotti M, Grazi M, Palermo P, Marenzi G. Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. *J Am Coll Cardiol* 2000;36:1600-4.
31. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *Lancet* 2001; 357:1915-24.
32. Marenzi G, Lauri G, Guazzi M, Assanelli E, Grazi M, Famoso G, Agostoni PG. Cardiac and renal dysfunction in chronic heart failure: relation to neurohumoral activation and prognosis. *Am J Med Sci* 2001; 321 (6): 359-366.
33. Salvioni A, Casilli F, Assanelli E, Grazi M, Marenzi G, Guazzi MD. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. *Thromb Haemost* 2001;86: 991-4.
34. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni PG. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. *J Am Coll Cardiol* 2001;38:963-8.
35. PG.Agostoni, G.Marenzi. Sustained benefit from ultrafiltration in moderate congestive heart failure. *Cardiology* 2001;96:183-189.
36. G. Marenzi, G.Lauri, E.Assanelli, M.Grazi, J.Campodonico, G.Famoso, P.Agostoni. Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure. *Eur J Heart Failure* 2002; 4:597-603.
37. G.Marenzi, AL.Bartorelli, G.Lauri, E.Assanelli, M.Grazi, J.Campodonico, I.Marana. Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. *Cathet Cardiovasc Intervent* 2003;58:59-64.
38. JP.Ottervanger, P.Armstrong, ES Barnathan et al , for the GUSTO IV-ACS Investigators. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina. One-year survival in the GUSTO IV-ACS (Global use of strategies to open occluded coronary arteries IV – acute coronary syndromes) trial. *Circulation* 2003;107:437-442.

39. G.Marenzi, I.Marana, G.Lauri, E.Assanelli, M.Grazi, J.Campodonico, D.Trabattoni, F.Fabbicocchi, P.Montorsi, AL.Bartorelli. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. *N Engl J Med* 2003;349:13331-1338.
40. Moruzzi P, Marenzi G, Callegari S, Contini M. Circadian distribution of acute myocardial infarction by anatomic location and coronary artery involvement. *Am J Med* 2004;116:24-27.
41. Marenzi G, Bartorelli AL. Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy: the authors reply. *N Engl J Med* 2004; 350:838.
42. Marenzi G., Bartorelli, AL. Hemofiltration for the prevention and treatment of contrast-induced nephropathy. *CardioUpdate* 2004 (February):14-15.
43. G. Marenzi, AL. Bartorelli. Hemofiltration in the prevention of radiocontrast agent induced nephropathy. *Minerva Anestesiol* 2004;70:189-191.
44. Ottenvager JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Wallentin L, Simoons ML, for the GUSTO IV-ACS Investigators. Association of revascularisation with low-mortality in non-ST elevation acute coronary syndrome, a report from the GUSTO IV-ACS. *Eur Heart J* 2004; 25:1494-1501.
45. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 2004;44:1780-5.
46. Marenzi G, Bartorelli A. Recent advances in the prevention of radiocontrast-induced nephropathy. *Curr Opinion Crit Care* 2004; 10:205-209.
47. G.Marenzi, P.Agostoni. Hemofiltration in heart failure. *Int J Artif Organs* 2004;27:1070-1076.
48. Lenderink T, Boersma E, Widimski P, et al. (Marenzi G). Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. *Am Heart J* 2004;147:865-73.
49. G. Marenzi. Can contrast-induced nephropathy after percutaneous coronary intervention be accurately predicted with a risk score? *Nature Clinical Practice Cardiovascular Medicine* 2005;2:80-81.
50. G.Marenzi, I.Marana, G.Lauri, E.Assanelli, M.Grazi, J.Campodonico, D.Trabattoni, F.Fabbicocchi, P.Montorsi, AL.Bartorelli. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. Extended abstract. *Compendium Series: Cardiovascular*. 2005;3:16-18.
51. Agostoni PG, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, Wasserman K. Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. *J Am Coll Cardiol* 2005; 9:1779-1781.
52. Marenzi G, Assanelli E, Bartorelli AL. Management of acute coronary syndromes in patients with renal insufficiency. *Current Cardiology Review* 2006;2:11-16.
53. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, Grazi M, Veglia F, Fabbicocchi F, Montorsi P, Bartorelli AL. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. *Am J Med* 2006; 119:155-162.

54. The OASIS-6 trial group (Dott. Marenzi). Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial. *JAMA* 2006; 295:15119-1530.
55. C. Briguori, G. Marenzi. Contrast-induced nephropathy: pharmacological prophylaxis. *Kidney International* 2006; 69:S30-S38.
- 56 R. Solomon, G. Deray on behalf of the Consensus Panel for CIN (Marenzi G). How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. *Kidney International* 2006; 69:S51-S53.
57. Trabattoni D, Bartorelli AL, Fabbicchi F, Montorsi P, Ravagnani P, Pepi M, Celeste F, Maltagliati A, Marenzi G, O'Neill WW. Hyperoxemic perfusion of the left anterior descending coronary artery after primary angioplasty in anterior ST-elevation myocardial infarction. *Cathet Cardiovasc Intervent* 2006; 67:859-65.
58. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbicchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med* 2006; 354:2773-82.
59. Marenzi G, Lauri G, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy. The Authors Reply. *N Engl J Med* 2006; 355:1499-1500.
60. Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. *Eur Heart J* 2006;21:2538-43.
61. Marenzi G, Moltrasio M, Assanelli E, Lauri G, Marana I, Grazi M, Rubino M, De Metrio M, Veglia F, Bartorelli AL. Impact of cardiac and renal dysfunction on in-hospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. *Am Heart J* 2007;153:755-762.
62. Marenzi G. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. www.siicsalud.com on, May 28th, 2007.
63. Marenzi G. Nefropatia inducida por el contraste en pacientes sometidos a angioplastia primaria por infarto agudo de miocardio. Section Expertos Invitados (Invited Experts) of SIIC On the Internet www.siicsalud.com. Sociedad Iberoamericana de Información Científica (SIIC) 2007.
64. Marenzi G, Bartorelli A. Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. *Eur Heart J* 2007;17:2172-3.
65. Marenzi G, Bartorelli A. Prevention of contrast-induced nephropathy in high-risk patients with hemofiltration. Author Reply. *Am J Med* 2007;120:e11.
66. Marenzi G, Bartorelli A. Primary angioplasty for acute myocardial infarction and the emerging role of renal insufficiency. *Interventional Cardiology* 2007;17-20.
67. Sisillo E, Ceriani R, Bortone F, Juliano G, Salvi L, Veglia F, Fiorentini C, Marenzi G. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery. A prospective, randomized, clinical trial. *Crit Care Med* 2008;36:81-86.
68. Marenzi G. Prophylactic hemodialysis for the prevention of contrast-induced nephropathy after coronary angiography. *Nature Clinical Practice* 2008;4:130-131.

69. Bartorelli A, Marenzi G. Contrast-induced nephropathy. *J Interv Cardiol* 2008;21:74-85.
70. Peters RJG, Joiner C, Bassand R, et al for the OASIS-6 investigators (G.Marenzi). The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. *Eur Heart J* 2008;29:324-31.
71. Oldgren J, Wallentin L, Afzal R, et al. for the OASIS-6 Investigators (G.Marenzi). Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. *Eur Heart J*. 2008;29:315-323.
72. Brambilla M, Camera M, Colnago D, Marenzi G, De Metrio M, Giesen PL, Balduini A, Veglia F, Gertow K, Biglioli P, Tremoli E. Tissue factor in patients with acute coronary syndromes. Expression in platelets, leukocytes, and platelet-leukocyte aggregates. *Arterioscler Thromb Vasc Biol* 2008;28:947-53.
73. Nyman U, Björk J, Aspelin P, Marenzi G. Contrast medium dose-to-GFR ratio. A measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. *Acta Radiol* 2008; 49(6):658-67.
74. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbicocchi F, Bartorelli A. Association of contrast volume during primary percutaneous coronary intervention with contrast-induced nephropathy and mortality. *Annals of Internal Medicine* 2009;150:170-177.
75. Cavalca V, Veglia F, Squellerio I, Marenzi G, Minardi F, De Metrio M, Cighetti G, Boccotti L, Ravagnani P, Tremoli E. Glutathione, vitamin E, and oxidative stress in coronary artery disease: relevance of age and gender. *Eur J Clin Invest* 2009;39 (4): 267–272.
76. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK, for the EARLY ACS Investigators (Marenzi G). Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. *New Engl J Med* 2009; 360:2176-90.
77. Grazi M, Lauri G, Carbucicchio C, Marenzi G. Use of levosimendan for the treatment of cardiogenic shock associated with electrical storm. *Annals of Internal Medicine* 2009;150:738-40.
78. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. *Am J Med* 2009;122: 874.e9-874.e15.
79. Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E (Marenzi G). Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. *Lancet* 2009;374:787-795.
80. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt, DL, for the Champion-PCI investigators (Marenzi G). Platelet Inhibition with cangrelor in patients undergoing PCI. *N Engl J Med* 2009;361.
81. Carbucicchio C, Della Bella P, Fassini G, Trevisi N, Riva S, Giraldi F, Baratto F, Marenzi G, Sisillo E, Bartorelli A, Alamanni F. Percutaneous cardiopulmonary support for catheter ablation of unstable ventricular arrhythmias in high-risk patients. *Herz*. 2009;34:545-52.

82. Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, Moltrasio M, Rubino M, Veglia F, Montorsi P, Bartorelli AL. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. *Crit Care Med* 2010; 38:438-44.
83. Banfi C, Brioschi M, Marenzi G, De Metrio M, Camera M, Mussoni L, Tremoli E. Proteome of platelets in patients with coronary artery disease. *Exp Hematol*. 2010;38:341-350.
84. Costanzo MR, Agostoni P, Marenzi G. Extracorporeal fluid removal in heart failure patients. *Contrib Nephrol*. 2010, 64:173-198.
85. Ammirati E, Cianflone D, Banfi M,, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Pallosi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airolidi F, Manfredi AA, Catapano AL, Norata GD. Circulating CD4⁺CD25^{hi}CD127^{lo} regulatory T-cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. *Arterioscler Thromb Vasc Biol* 2010; 30(9):1832-41.
86. Agostoni P, Banfi C, Brioschi M, Magri D, Sciomer S, Berna G, Brambillasca C, Marenzi G, Sisillo E. SPB and RAGE increases in the plasma during cardiopulmonary by-pass: a pilot study. *Eur Respir J* 2010 Jul 22.
87. Marenzi G, Giorgio M, Trinei M, Moltrasio M, Ravagnani P, Cardinale C, Ciceri F, Cavallero A, Veglia F, Fiorentini C, Cipolla CM, Bartorelli AL, Pelicci P. Circulating cytochrome C as a potential biomarker of impaired reperfusion in ST-elevation acute myocardial infarction. *Am J Cardiol* 2010;106:1443-1449.
88. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P, Achilli F, Martelli F, Maggiolini S, Marenzi G, Pompilio G, Capogrossi MC. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. *Eur Heart J* 2010;31:2765-73.
89. Marenzi G, De Metrio M, Rubino M, Lauri G, Cavallero A, Assanelli E, Grazi M, Moltrasio M, Marana I, Campodonico J, Discacciati A, Veglia F, Bartorelli A. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. *Am Heart J* 2010; 160:1170-1177.
90. Agostoni P, Banfi C, Brioschi M, Magri D, Sciomer S, Berna G, Brambillasca C, Marenzi G, Sisillo E. Surfactant protein B and RAGE increases in the plasma during cardiopulmonary by-pass: a pilot study. *Eur Respir J* 2011;37:1-7.
91. Sisillo E, Marenzi G. N-Acetylcysteine for the prevention of acute kidney injury after cardiac surgery. *J Clin Pharmacol* 2011; 51(11):1603-10.
92. Colombo G, Gertow K, Marenzi G, Brambilla M, De Metrio M, Tremoli E, Camera M. Gene expression profiling reveals multiple differences in platelets from patients with stable angina or non-ST elevation acute coronary syndrome. *Thrombosis Research* 2011; 128(2):161-8.
93. Marenzi G. How safe are iodinated contrast media? *Daily Congress News ERA-EDTA*, Issue 1/June 23, 2011:12-13.
94. Marenzi G, De Metrio M, Bartorelli A. Author's reply to acute hyperglycemia: Is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function? *Am Heart J* 2011;162:e9.

95. Agostoni P, Banfi C, Magri D, Vignati C, Doria E, Salvioni E, Moliterni P, Marenzi G, Tremoli E, Sisillo E. Kinetics of plasma SBP and RAGE during mechanical ventilation in patients undergoing major vascular surgery. *Respiratory Physiology & Neurobiology* 2011;178:256-260.
96. Alexander JH, Lopes RD, James S, et al. for the APPRAISE-2 Investigators* (Dott. G. Marenzi). Apixaban with antiplatelet therapy after acute coronary syndrome. *New Engl J Med* 2011;365:699-708.
97. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Jan G.P. Tijssen JGP, Van de Werf F, Wallentin L, for the RE-DEEM investigators (Dott. G. Marenzi). Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J* 2011;32:2781-2789.
98. Cristell N, Cianflone D, Durante A, Ammirati E, Vanuzzo D, Banfi M, Calori G, Latib A, Crea F, Marenzi G, De Metrio M, Moretti L, Li H, Uren NG, Hu D, Maseri A on behalf of the FAMI Study Investigators. High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases. A multiethnic case-control study. *J Am Coll Cardiol* 2011;58:2654-2661.
99. Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy. A systematic review. *Am J Med* 2012;125:66-78.
100. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, Veglia F, Fabbicocchi F, Montorsi P, Bartorelli AL. Prevention of Contrast Nephropathy by Furosemide With Matched Hydration. The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) Trial. *J Am Coll Cardiol Interv* 2012; 5:90-97.
101. Klima T, Christ A, Marana I, Kalbermatter S, Uthoff H, Burri E, Hartwiger S, Schindler C, Breidthardt T, Marenzi G, Mueller C. Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. *Eur Heart J* 2012;33:2071-9.
102. Lippi G, Cappelletti P, Plebani M, Vernocchi A, Cavazza M, Di Somma S, Monzani V, Moscatelli P, Galvani M, Marenzi G, Tubaro M, Volpe M, Ferraro S, Wratten ML, A. Lombardi A, Peracino A. Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of Copeptin. *Clinical Chemistry and Laboratory Medicine* 2012; 50:243-53.
103. Morrow DA, Braunwald E, Bonaca MP, et al. For the TRA 2P-TIMI 50 Study Group (G. Marenzi). Vorapaxar in the Secondary Prevention of Atherothrombotic Events. *New Engl J Med* 2012; 366:1404-1413.
104. De Metrio M, Milazzo V, Marenzi G. Serum vitamin D concentration status and its correlation with early biomarkers of remodeling following acute myocardial infarction. *Clin Res Cardiol* 2012;101:771-2.
105. Marenzi G, Ferrari C, Bartorelli AL. Hydration is critical for prevention of contrast-induced nephropathy. Reply. *J Am Coll Cardiol Interv* 2012; 5 (4):455-456.
106. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Tramontana S, Manfredi A, Catapano AL, Maseri A, Palini A, Norata GD. Effector memory lymphocyte T cells are associated with atherosclerosis in humans and animal models. *J Am Heart Association* 2012;1:27-41.

107. Olivari Z, Steffenino G, Savonitto S, Chiarella F, Chinaglia A, Lucci D, Maggioni AP, Pirelli S, Scherillo M, Scorcu G, Tricoci P, Urbinati S (on behalf of BLITZ 4 Investigators) (Marenzi G, Assanelli E). The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità: campaign for performance measurement and quality improvement. *European Heart Journal: Acute Cardiovascular Care* 2012; published online 29 May 2012
108. Maugeri N, Rovere-Querini P, Evangelista V, Godino C, De Metrio M, Baldini M, Figini F, Coppi G, Slavich M, Camera M, Bartorelli A, Marenzi G, Campana L, Baldissera E, Sabbadini MG, Cianflone D, Tremoli E, D'Angelo A, Manfredi AA, Maseri A. An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. *Plos One* 2012;7:e39484.
109. Ammirati E, Cannistraci CV, Cristell NA, Vecchio V, Palini AG, Tornvall P, Paganoni AM, Miendlarzewska EA, Sangalli LM, Monello A, Pernow J, Bennermo MB, Marenzi G, Hu D, Uren NG, Cianflone D, Ravasi T, Manfredi AA, Maseri A. Identification and Predictive Value of IL6(+)IL10(+) and IL6(-)IL10(+) Cytokine Patterns in ST-Elevation Acute Myocardial Infarction. *Circulation Research* 2012;111:1336-48.
110. Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA; TRA 2P-TIMI 50 Steering Committee Investigators (Marenzi G.). Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a pre-specified subgroup analysis of the TRA 2P-TIMI 50 trial. *Lancet* 2012;380:1317-24.
111. Osthoff M, Piezzi V, Klima T, Christ A, Marana I, Hartwiger S, Breidthardt T, Marenzi G, Trendelenburg M, Mueller C. Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. *BMC nephrology* 2012;13:99.
112. Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G; on behalf of the SMILE-4 Working Party (Marenzi G). Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: Results of a randomized, double-blind, parallel-group, multicenter, european study (SMILE-4). *Clin Cardiol* 2012; 35:416-423.
113. Marenzi G, Cabiati A, Milazzo V, Rubino M. Contrast-induced nephropathy. *Intern Emerg Med* 2012; 7(Suppl 3):S181-S183.
114. Cavalca V, Veglia F, Squellerio I, De Metrio M, Rubino M, Porro B, Moltrasio M, Tremoli E, Marenzi G. Circulating levels of dimethylarginines chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction. *Plos One* 2012; 7 (11): e48499.
115. Marenzi G, Cabiati A, Assanelli E. Chronic kidney disease in acute coronary syndromes. *World J Nephrol* 2012 October 6; 1(5): -000.
116. Marenzi G, Cabiati A, Bertoli SV, Assanelli E, Marana I, De Metrio M, Rubino M, Moltrasio M, Grazi M, Campodonico J, Milazzo V, Veglia F, Lauri G, Bartorelli AL. Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. *Am J Cardiol* 2013; 111(6):816-22.
117. Marenzi G, Aspromonte N. Ultrafiltration in refractory heart failure. *J Am Coll Cardiol* 2013; 61:1658-9.

118. Ammirati E, Cristell NA, Cianflone D, Vermi AC, Marenzi G, De Metrio M, Uren N, Hu D, Ravasi T, Maseri A, Cannistraci CV. Questing for circadian dependence in ST elevation acute myocardial infarction: a multi-centric and multiethnic study. *Circ Research* 2013;112(10):110-4.
119. Bartorelli A, Ferrari C, Fabbionchi F, Montorsi P, Tamborini G, Sisillo E, Andreini D, Pontone G, Marenzi G, Alamanni F. TAVI with RenalGuard™ therapy in an elderly patient with chronic kidney disease. *TAVItalk Case Report*. Quarter 1, 2013/Italy.
120. Borghi C, Ambrosioni E, Omboni S, Cicero AF, Bacchelli S, Esposti DD, Vinereanu D, Ambrosio G, Zava D; SMILE-4 Working Party (G. Marenzi). Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. *J Hypertens* 2013;31:1256-64.
121. Steg PG, Mehta SR, Pollack CV, Bode C, Cohen M, et al. for the TAO Investigators (Marenzi G). Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes. The TAO randomized clinical trial. *JAMA* 2013;18;310(11):1145-55.
122. Nicholls SJ, Kastelein JJP, Schwartz GG, et al. for the VISTA-16 Investigators (Marenzi G). Varespladib and cardiovascular events in patients with an acute coronary syndrome. The VISTA-16 Randomized Clinical Trial. *JAMA* 2013 Nov 18. [Epub ahead of print].
123. D'Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P, Rubino M, Marenzi G, Colombo GI, Achilli F, Maggiolini S, Capogrossi MC, Pompilio G. Diagnostic Potential of Plasmatic MicroRNA Signatures in Stable and Unstable Angina. *PLoS One* 2013;8:e80345.
124. Marenzi G, Muratori M, Cosentino ER, Rinaldi ER, Donghi V, Milazzo V, Ferramosca E, Borghi C, Santoro A, Agostoni P. Continuous ultrafiltration for congestive heart failure. The Cuore Trial. *J Card Fail* 2014;20:9-17.
125. Nicholls SJ, Kastelein JJP, Schwartz GG, et al. for the VISTA-16 Investigators (Marenzi G). Varespladib and cardiovascular events in patients with an acute coronary syndrome. The VISTA-16 Randomized Clinical Trial. *JAMA* 2014;311:252-262.
126. Marana I, Marenzi G, Kazori A. Extracorporeal ultrafiltration for heart failure: focus on organ cross talk and clinical trials. *Nephrol Ther* 2014;10(4):203-9.
127. Moltrasio M, Cabiati A, Milazzo V, Rubino M, De Metrio M, Discacciati A, Rumi P, Marana I, Marenzi G. B-type natriuretic peptide and risk of acute kidney injury in patients hospitalized with acute coronary syndromes. *Crit Care Med* 2014;42:619-624.
128. Marenzi G, Mazzotta G, Londrino F, Gistri R, Moltrasio M, Cabiati A, Assanelli E, Veglia F, Rombolà G. Post-procedural hemodiafiltration in acute coronary syndrome patients with associated renal and cardiac dysfunction undergoing urgent and emergency coronary angiography. *Catheter Cardiovasc Interv* 2015;85:345-51.
129. De Luca L, Leonardi S, Cavallini C, Lucci D, Musumeci G, Caporale R, Abrignani MG, Lupi A, Rakar S, Gulizia MM, Bovenzi FM, De Servi S on behalf of the EYESHOT Investigators (G. Marenzi). Contemporary Antithrombotic Strategies in Patients with Acute Coronary Syndromes Admitted To Cardiac Care Units in Italy: The EYESHOT Study. *Eur Heart J Acute Cardiovasc Care*. 2014 Nov 20. (Epub ahead of print).

130. Zeymer U, Heuer H, Schwimmbeck P, Genth-Zotz S, Wolff K, Nienaber CA; The EPICOR Investigators (G. Marenzi). Guideline-adherent therapy in patients with acute coronary syndromes : The EPICOR registry in Germany. *Herz* 2014 Nov 7. [Epub ahead of print]
131. Pocock S, Bueno H, Licour M, Medina J, Zhang L, Annemans L, Danchin N, Huo Y, Van de Werf F. Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-term follow up of antithrombotic management patterns in acute CORonary syndrome patients) study (G. Marenzi). *Eur Heart J Acute Cardiovasc Care*. 2014 Oct 9. [Epub ahead of print].
132. Sinnaeve PR, Zeymer U, Bueno H, Danchin N, Medina J, Sánchez-Covisa J, Licour M, Annemans L, Jukema JW, Pocock S, Storey RF, Van de Werf F. Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study (G. Marenzi). *Eur Heart J Acute Cardiovasc Care*. 2014 Sep 10.[Epub ahead of print]
133. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA. New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2P-TIMI 50 Trial (G. Marenzi). *J Am Coll Cardiol*. 2014 Dec 9;64(22):2318-26. doi: 10.1016/j.jacc.2014.07.997. Epub 2014 Dec 1.
134. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, Morrow DA. Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2P-TIMI 50 Trial (G. Marenzi). *J Am Coll Cardiol*. 2014 Dec 9;64(22):2309-17. doi: 10.1016/j.jacc.2014.09.037. Epub 2014 Dec 1.
135. Marenzi G, Kazory A, Agostoni P. Ultrafiltration for congestive heart failure; the past and the present. *Curr Opin Cardiol* 2015.
136. Marenzi G, Morpurgo M, Agostoni P. Continuous ultrafiltration in acute decompensated heart failure: Current issues and future directions. *Am J Cardiovasc Drugs* 2015.
137. Marenzi G, Cosentino N, Guastoni C. How to balance risks and benefits in the management of CKD patients with coronary artery disease. *J Nephrol* 2015.
138. Marenzi G, Cabiati A, Cosentino N, Assanelli E, Milazzo V, Rubino M, Lauri G, Morpurgo M, Moltrasio M, Marana I, De Metrio M, Bonomi A, Veglia F, Bartorelli A. Prognostic significance of serum creatinine and its change patterns in patients with acute coronary syndromes. *Am Heart J* 2015;169(3):363-70.
139. Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. *Int J Cardiol*. 2015;183:47-53.
140. Bonaca MP, Bhatt DL, Cohen M, et al. for the PEGASUS Steering Committee and Investigators (Marenzi G). Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015;372:1791-1800.
141. De Metrio M, Milazzo V, Rubino M, Cabiati A, Moltrasio M, Marana I, Campodonico J, Cosentino N, Veglia F, Bonomi A, Camera M, Tremoli E, Marenzi G. Vitamin D plasma levels and in-hospital and 1-year outcomes in acute coronary syndromes: a prospective study. *Medicine* 2015; 94:1-8.
142. Cannon CP, Blazing MA, Giugliano RP, et al. for the IMPROVE-IT Investigators (Marenzi G). *N Engl J Med*. 2015 Jun 3

143. Marenzi G, Cosentino N, Bartorelli A. Acute kidney injury in patients with acute coronary syndromes. *Heart* 2015.
144. Ronco C, Antonelli M, Capasso G, De Gaudio R, Fiaccadori E, Lorini L, Mancini E, Monti G, Morabito S, Nalesso F, Piccinni P, Ricci Z, Romagnoli S, Santoro A, Aresu S, De Rosa S, Samoni S, Spinelli A, Villa G, Armignacco P, Basile C, Biancofiore G, Cantaluppi V, Cerutti S, De Pascalis A, Fumagalli R, Garzotto F, Gaspardone A, Genovesi S, Guggia S, Inguaggiato P, Lorenzin A, Marenzi G, Mariano F, Neri M, Pani A, Pertosa G, Pistolesi V, Sartori M. Guidelines for the prevention, diagnosis and treatment of acute kidney injury syndromes: Italian version of KDIGO, integrated with new evidence and international commentaries. *G Ital Nefrol* 2015 Mar-Apr;32(2).
145. De Luca L, Leonardi S, Smecca IM, et al. on behalf of the EYESHOT Investigators (Marenzi G, Assanelli EM). Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularizations: insights from the EYESHOT study. *Eur Heart J Cardiovascular Pharmacotherapy* 2015;1:168-178.
146. Avanzini F, Mafrici A, Riva E, et al on behalf of GLICYNE-SPIDER Collaborative Group (Marenzi G). A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndromes. *Nutrition, Metabolism & Cardiovascular Diseases* 2015.
147. Bohula EA, Giugliano RP, Cannon CP et al. for the IMPROVE-IT Investigators (Marenzi G, Moltrasio M). Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. *Circulation* 2015, 32:1224-1233.
148. De Luca L, Leonardi S, Cavallini C, Lucci D, Musumeci G, et al. for the EYESHOT investigators (Marenzi G). Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT Study. *Eur Heart J Acute Cardiovasc Care* 2015;4:441-52.
149. Marenzi G, Cosentino N, Cortinovis S, Milazzo V, Rubino M, Cabiati A, De Metrio M, Moltrasio M, Lauri G, Campodonico J, Pontone G, Andreini D, Bonomi A, Veglia F, Bartorelli A. Myocardial infarct size in patients on long-term statin therapy undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Cardiol.* 2015;116:1791-7.
150. Moltrasio M, Cosentino N, De Metrio M, Rubino M, Cabiati A, Milazzo V, Discacciati A, Marana I, Bonomi A, Veglia F, Lauri G, Marenzi G. Brain natriuretic peptide in acute myocardial infarction: a marker of cardio-renal interaction. *J Cardiovasc Med* 2016;17:803-9.
151. Marenzi G, Kazory A. The AVOID-HF Trial: Points to consider. *JACC: Heart Failure* 2016; 4:311.
152. Lauri G, Rossi C, Rubino M, Cosentino N, Milazzo V, Marana I, Cabiati A, Moltrasio M, De Metrio M, Grazi M, Campodonico J, Assanelli E, Riggio D, Sandri MT, Bonomi A, Veglia F, Marenzi G. B-type natriuretic peptide levels in patients with pericardial effusion undergoing pericardiocentesis. *Int J Cardiol* 2016;212:318-323.
153. Marenzi G, Cosentino N, Moltrasio M, Rubino M, Crimi G, Buratti S, Grazi M, Milazzo V, Somaschini A, Camporotondo R, Cornara S, De Metrio M, Bonomi A, Veglia F, De Ferrari GM, Bartorelli AL. Acute kidney injury definition and in-hospital mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. *J Am Heart Assoc* 2016.

154. Nieminen MS, Buerke M, Cohen-Solál A, Costa S, Édes I, Erlikh A, Franco F, Gibson C, Gorjup V, Guarracino F, Gustafsson F, Harjola VP, Husebye T, Karason K, Katsytadze I, Kaul S, Kivikko M, Marenzi G, Masip J, Matskeplishvili S, Mebazaa A, Møller JE, Nessler J, Nessler B, Ntalianis A, Oliva F, Pichler-Cetin E, Pöder P, Recio-Mayoral A, Rex S, Rokyta R, Strasser RH, Zima E, Pollesello P. The role of levosimendan in acute heart failure complicating acute coronary syndrome: a review and expert consensus opinion. *Int J Cardiol* 2016;218:150-7.
155. Marenzi G, Cosentino N, Boeddinghaus J, Trinei M, Giorgio M, Milazzo V, Moltrasio M, Cardinale D, Sandri MT, Veglia F, Bonomi A, Kaech M, Twerenbold R, Nestelberger T, Reichlin T, Wildi K, Shrestha S, Kohzuharov N, Sabti Z, Cipolla CM, Mueller C, Bartorelli AL. Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction. *Circulation Research* 2016;119:1339-1346.
156. Bonaca MP, Gutierrez JA, Creager MA, et al. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis—Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50) (Marenzi G). *Circulation*. 2016;133:997-1005.
157. Bonaca MP, Goto S, Bhatt DL, et al. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (Marenzi G). *Circulation* 2016 134:861-71.
158. Bonaca MP, Bhatt DL, Oude Ophuis T, et al. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial (Marenzi G). *JAMA Cardiol* 2016;1:425-32.
159. Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial (Marenzi G). *J Am Coll Cardiol* 2016;67:1145-54.
160. Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (Marenzi G). *Eur Heart J*. 2016;37:1133-42.
161. Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial (Marenzi G). *Eur Heart J* 2016;37:400-8.
162. Eisen A, Cannon CP, Blazing MA, et al. for the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators (Marenzi G). The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. *Eur Heart J* 2016;37:3576-3584.
163. Murphy SA, Cannon CP, Blazing MA, et al (Marenzi G). Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. *J Am Coll Cardiol* 2016;67:353-61.
164. Marenzi G, Cosentino N, Marinetti A, Leone AM, Milazzo V, Rubino M, De Metrio M, Cabiati A, Campodonico J, Moltrasio M, Bertoli S, Cecere M, Mosca S, Marana I, Grazi M, Lauri G, Bonomi A, Veglia F, Bartorelli AL. Renal replacement therapy in patients with acute myocardial infarction: Rate of use, clinical predictors and relationship with in-hospital mortality. *Int J Cardiol* 2017;230:255-261.

165. Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators (Marenzi G). Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2017;69:176-185.
166. Milazzo V, De Metrio M, Cosentino N, Marenzi G, Tremoli E. Vitamin D and acute myocardial infarction. *World J Cardiol* 2017;9:14-20.
167. Bartorelli AL, Marenzi G. High urine output with matched hydration for CI-AKI prevention. "Salus Per Aquam" (Health Through Water)". *JACC: Cardiovascular Intervention* 2017; 10(4):364-6.
168. Marc S. Sabatine MS, Giugliano RP, Keech, AC, et al. for the FOURIER Steering Committee and Investigators (Marenzi G). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med* 2017; 376:1713-1722 (I.F.59.558).
169. Maria Rosa Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, Gottlieb SS, Jaski BE, Kazory A, Levin AP, Levin HR, Marenzi G, Mullens W, Negoianu D, Redfield MM, Tang WHW, Testani JM, Voors AA. Extracorporeal ultrafiltration for the treatment of fluid overload in heart failure: critical evaluation of current status and appeal for further research. *J Am Coll Cardiol* 2017;69:2428-45.
170. Cosentino N, Milazzo V, Campodonico J, Marenzi G. Acute kidney injury in patients with ST-elevation myocardial infarction. *Journal of Heart and Stroke* 2017
171. Morpurgo M, Pasqualini M, Brunazzi MC, Vianello G, Valle R, Roncon L, Fiorini F, Aspromonte N, Barbiero M, Goldoni M, Marenzi G. A multicenter feasibility study on ultrafiltration via a single peripheral venous access in acute heart failure with overt fluid overload. *Int J Cardiol* 2017.
172. Pontone G, Guaricci AI, Andreini D, Ferro G, Guglielmo M, Baggiano A, Fusini L, Muscogiuri G, Lorenzoni V, Mushtaq S, Conte E, Annoni A, Formenti A, Mancini ME, Carità P, Verdecchia M, Pica S, Fazzari F, Cosentino N, Marenzi G, Rabbat MG, Agostoni P, Bartorelli AL, Pepi M, Masci PG. Prognostic stratification of patients with ST-segment-elevation myocardial infarction (PROSPECT). A Cardiac Magnetic Resonance Study. *Circ Cardiovasc Imaging*. 2017;10:e006428. DOI: 10.1161/CIRCIMAGING.117.006428.
173. Milazzo V, Cosentino N, Marenzi G. Extracorporeal ultrafiltration for acute heart failure: patient selection and perspectives. *Vascular Health and Risk Management* 2017;13 449-456.

Original articles on italian journals.

1. CM.Cipolla, A.Rimondini, P.Della Bella, F.Fabbiocchi, S.Grazi, G.Marenzi, P.Sganzerla, C.Tondo, E.Sisillo, G.Susini. Trattamento acuto dello scompenso cardiaco congestizio refrattario a terapia medica mediante emofiltrazione. *Cardiologia* 1987;32:69-72.
2. A.Rimondini, CM.Cipolla, P.Della Bella, S.Grazi, G.Marenzi, E.Sisillo, G.Susini, C.Tondo, MD.Guazzi. L'emofiltrazione rimedio acuto allo scompenso cardiaco intrattabile. Linee guida per una corretta attuazione. *Cardiologia* 1987; 32:747-752.

3. P.Della Bella, G.Marenzi, F.Doni, C.Tondo, C.Cipolla, S.Grazi, A.Rimondini, A.Salvioni, MD.Guazzi. Efficacia della disopiramide nel trattamento del flutter atriale mediante stimolazione overdrive. *Cardiologia* 1989;3:247-252.
4. CM.Cipolla, A.Rimondini, P.Della Bella, A.Salvioni, C.Tondo, G.Marenzi, F.Giraldi, D.Cardinale, G.Susini, S.Grazi, MD.Guazzi. Modificazioni neuromorali indotte dalla emofiltrazione nello scompenso congestizio: influenze fisiopatologiche. *Cardiologia* 1990;3:223-231,1990.
5. F.Giraldi, CM.Cipolla, P.Della Bella, G.Marenzi, A.Salvioni, MD.Guazzi. Neurohumoral changes induced by hemofiltration treatment of refractory congestive heart failure. Second World Week of Professional Updating in Surgery and in Surgical and Oncological Disciplines of the University of Milan. Free Papers Printed in Full. 1990;VIII303-VIII307.
6. P.Della Bella, G.Marenzi, C.Tondo, F.Giraldi, M.Guazzi. Atrial flutter termination by overdrive pacing: relation to changes of excitable gap induced by different antiarrhythmic drugs. In Furlanello, Vergara, Bettini Editors: *The New Frontiers of Arrhythmias* 1990:891-894.
7. A.Salvioni, G.Marenzi. La terapia antitrombotica nell'infarto miocardico. *La Rivista Del Medico Pratico* 1991;376 (*Cardiologia* 85):7-20.
8. G.Marenzi, PG.Agostoni, G.Lauri, GB.Perego, M.Grazi, M.Schianni, F.Giraldi, A.Salvioni, M.Guazzi. Interrelazione tra volume plasmatico, metabolismo idrico ed attivazione neuroormonale dopo ultrafiltrazione nello scompenso cardiaco congestizio. *Cardiologia* 1992;37:831-837.
9. MD.Guazzi, G.Marenzi, M.Pepi, G.Lauri, M.Alimento, S.Riva, P.Agostoni. The pathophysiological meaning of overhydration of the lung in moderate heart failure. International Workshop on "The role of cardiac ultrasound in major cardiac syndromes" Bari 1993, *Proceedings*:57-58.
10. G.Marenzi, S.Grazi, A.Salvioni, G.Lauri, GB.Perego, M.Guazzi, PG.Agostoni. Studio dei fattori che regolano il metabolismo idrosalino nello scompenso cardiaco congestizio. *Cardiologia* 1993;38:287-295.
11. PG.Agostoni, G.Marenzi, M.Pepi, E.Doria, M.Schianni, A. Salvioni, G.Perego, G.Lauri, F.Giraldi, S.Grazi. Modificazioni delle caratteristiche fisiche del polmone possono spiegare il miglioramento osservato dopo ultrafiltrazione nei pazienti con scompenso cardiaco moderato. *Cardiologia* 1993;7:425-429.
12. G.Lauri, G.Marenzi, PG.Agostoni, S.Grazi, G.Perego, A.Salvioni, E.Assanelli, C.Capobianco, G.Maggi, MD.Guazzi. Scompenso cardiaco moderato: il consumo di ossigeno durante esercizio è predittivo del risultato della ultrafiltrazione. *Cardiologia* 1994;4:253-259.
13. M.Guazzi, G.Marenzi, G.Cattadori, GB.Perego, G.Lauri, PG.Agostoni. Calcolo del rapporto spazio morto/volume corrente (VD/VT) nello scompenso cardiaco durante esercizio. *Cardiologia* 1994.
14. Marenzi G, Guazzi M, Lauri G, Perego GB, Sganzerla P, Agostoni PG. La rimozione di liquido corporeo con ultrafiltrazione produce persistente miglioramento della capacità funzionale del soggetto con insufficienza cardiaca congestizia cronica. La furosemide non dà lo stesso risultato. *Cardiologia* 1994;39:763-772.
15. Marenzi G, Lauri G, Guazzi M, Perego GB, Matturri M, Salvioni A, Giraldi F, Agostoni PG. Inibizione dell'asse neuromorale dopo deplezione di fluido intravascolare nello scompenso cardiaco congestizio con ritenzione idrica: meccanismi di perpetuazione della sindrome. *Cardiologia* 1995;40:15-22.

16. M.Guazzi, PG.Agostoni, G.Marenzi, G.Cattadori, GB.Perego, G.Lauri, MD.Guazzi. Calcolo del rapporto spazio morto/volume corrente nello scompenso cardiaco durante esercizio. *Cardiologia* 1995;40(3):167-172.
17. M.Pepi, GC.Marenzi, PG.Agostoni, E.Assanelli, GB.Perego, C.Galli. Exercise performance in dilated cardiomyopathy is related to both the diastolic and the systolic function of the heart. *International Course on ADVANCES IN CARDIAC ULTRASOUND. PROCEEDINGS. Bari 1995. pag. 76-77.*
18. G.Marenzi. L'ultrafiltrazione extracorporea. *Cardiologia* 1996; 41(6):571-573.
19. A.Salvioni, G.Marenzi. L'angina instabile: dalla fisiopatologia al trattamento. *La Rivista Del Medico Pratico* 1996; 512 (CARDIOLOGIA 98):5-17.
20. E.Assanelli, G.Marenzi, M.Grazi, G.Lauri, M.Guazzi, G.Cattadori, PG.Agostoni. Durata dei benefici dell'ultrafiltrazione nei pazienti con scompenso cardiaco moderato. *Cardiologia* 1997; 42(1):95-98.
21. PG.Agostoni, E.Assanelli, M.Guazzi, M.Grazi, GB.Perego, M.Lomanto, G.Cattadori, G.Lauri, G.Marenzi. Meccanismi di facilitazione della cessione di ossigeno durante esercizio nel paziente con scompenso cardiaco cronico. *Cardiologia* 1997;Vol.42, n.7:743-50.
22. G.Marenzi, G.Lauri, E.Assanelli, M.Grazi, M.Guazzi, G.Berna, A.Salvioni, PG.Agostoni. Influenza dell'ACE-inibizione sull'escrezione elettrolitica urinaria e sul suo adattamento all'ipovolemia transitoria nello scompenso cardiaco cronico. *Cardiologia* 1997;42(12):1277-1283.
23. Cattadori G, Guazzi M, Marenzi GC, Campodonico J, Agostoni PG. Influenza della cardiomegalia sullo stato anatomico e funzionale del polmone nello scompenso cardiaco cronico. *Cardiologia* 1998;43 (3):295-301.
24. A.Salvioni, F.Giraldi, E.Assanelli, G.Lauri, M.Grazi, S.Pardea, GC.Marenzi. Attivazione piastrinica nelle prime fasi dell'infarto miocardico acuto. *Cardiologia* 1998;43(8):825-832.
25. G.Marenzi, M.Grazi, G.Susini, G.Lauri, E.Assanelli, M.Guazzi, PG.Agostoni. Volumi intra- ed extravascolari nello scompenso cardiaco congestizio refrattario e loro redistribuzione a seguito di ultrafiltrazione extracorporea. *Cardiologia* 1998; 43(11):1193-1200.
26. G.Marenzi, M.Grazi, E.Assanelli, F.Lavarra, PG.Agostoni. Strategie terapeutiche nel paziente con scompenso cardiaco estremo: ruolo dell'ultrafiltrazione. *Cardiologia* 1998; 43(Suppl.2):321-324.
27. PG.Agostoni, G.Cattadori, G.Pontone, M.Guazzi, G.Marenzi. Il polmone nello scompenso cardiaco refrattario. *Cardiologia* 1998; 43(Suppl.2):893-895.
28. PG.Agostoni, G.Marenzi. Terapia non farmacologica dello scompenso cardiaco estremo. *Cardiologia* 1999;44 (Suppl 3):25-28.
29. Marenzi G. Il polmone nella cardiomiopatia dilatativa. Volume degli Atti del Congresso: "Interazioni Cuore e Polmone", Torino 10-12 febbraio 2000, pag.7-10.
30. Agostoni P, Guazzi M, Doria E, Marenzi G. Pulmonary hemodynamic and tidal volume changes during exercise in heart failure. *Ital Heart J* 2002;3(2):104-108.

31. G.Marenzi, G.Lauri, E.Assanelli, M.Grazi, J.Campodonico, G.Famoso, P.Agostoni. Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure. *Eur J Heart Failure* 2002; 4:597-603.
32. F.Ottani, M.Galvani, A.Dolci, M.Plebani, M.Tubaro, M.Zaninotto, M.Panteghini, a nome del Gruppo di Studio Interdisciplinare Intersocietario ANMCO-SIBioC-SIMeL "Marcatori di Lesione Cardiaca". *Ital Heart J Suppl* 2002;3(9):933-942.
33. PG. Agostoni, G.Marenzi. Il trattamento del paziente con scompenso cardiaco refrattario. *La Cardiologia nella Pratica Clinica* 2003, vol 10, n.1:67-75.
34. G. Marenzi, P. Agostoni. Emofiltrazione nell'insufficienza cardiaca. *Nephro News* 2005;6:33-40.
35. L. Oltrona, A.Mafrici, M.Marzegalli, C.Fiorentini, R.Pirola, A.Vincenti, a nome dei Partecipanti allo Studio GestIMA (G. Marenzi). La gestione della fase iperacuta dell'infarto miocardico con soprasslivellamento del tratto ST nella Regione Lombardia (GestIMA). *Ital Heart J* 2005;6 (Suppl. 8):489-497.
36. Marzegalli M, Oltrona L, Corrada E, Fontana G, Klugman S a nome del Gruppo di Lavoro per l'Emergenza Cardiologica Extraospedaliera (G. Marenzi). La rete per la gestione delle sindromi coronariche acute nella città di Milano: risultati di quattro anni di esperienza e prospettive del network cardiologico preospedaliero ed interospedaliero. *Ital Heart J* 2005;6 (Suppl 6):49S-56S.
37. Marenzi G, Marana I, Agostoni P. Trattamenti extracorporei nell'insufficienza cardiaca: fisiopatologia, indicazioni cliniche e risultati. *G Ital Nefrol* 2006; 23 (suppl 36):S46-51.
38. G.Marenzi, G.Lauri, I.Marana, M.Moltrasio, M.Rubino, C.Fiorentini. Terapie sostitutive renali in cardiologia. *Hospital & Public Health* 2006; 1:40-47.
39. Marenzi G, Marana I, Bartorelli A. Attuali conoscenze sul controllo delle complicanze renali dell'angioplastica primaria. *Recenti Progressi in Medicina* 2007; 98:367-372.
40. Marenzi G. La prevenzione della nefropatia da mezzo di contrasto e la gestione del paziente a rischio. *Giornale Italiano di Cardiologia* 2009; 10(2):88-96.
41. Marenzi G, Marana I. La prevenzione dell'insufficienza renale. Quali soluzioni utilizzare nel rimpiazzo volêmico (emagel, mannitolo, reidratanti, ringer)? Quando e come utilizzare il diuretico? Quando far intervenire il nefrologo? *Atti del Congresso di Ecocardiochirurgia* 2011.
42. Braga F, Dolci A, Cavallero A, Ghezzi A, Infusino I, Milano M, Rubino M, Marenzi G, Panteghini M. Valutazione della sensibilità diagnostica per l'infarto miocardico senza soprasslivellamento del tratto ST (NSTEMI) di due metodi ad alta sensibilità per la troponina cardiaca. *Biochimica Clinica* 2011;35:186-189.
43. Marenzi G, Bertoli S, Marana I, Agostoni PG. Dall'ultrafiltrazione alla dialisi: indicazioni e obiettivi nei pazienti con insufficienza cardiaca. *Atti 45° Congresso Cardiologia* 2011 (Niguarda).
44. Fiaccadori E, Regolisti G, Marenzi G. Processo ai grandi trial: lo studio CARRESS. *G Ital Cardiol* 2013; 14:405-411.
45. Marenzi G, Briguori C. Processo ai grandi trial: lo studio PRATO-ACS. *G Ital Cardiol* 2013;14:803-808.
46. Briguori C, Napolitano G, Marenzi G. The POSEIDON study. *G Ital Cardiol* 2014;15(7):397-401.
47. Marenzi G, Paino R. Fenoldopam nei pazienti con insufficienza renale acuta postoperatoria. *G Ital Cardiol* 2015;16(3):129-33.

48. Milazzo V, Cosentino N, Marenzi G. Rischio cardiovascolare nel paziente con insufficienza renale cronica. Medico e Paziente 2017.

Book Chapters

1. Ultrafiltrazione ed emofiltrazione. GC.Marenzi, PG. Agostoni, M.Guazzi. In: Trattato di Cardiologia (ANMCO) 2001. Vol. II, Sezione IX (Insufficienza Cardiaca) pag. 1617-1628.
2. Terapia respiratoria della insufficienza cardiaca. PG. Agostoni, GC.Marenzi In: Trattato di Cardiologia (ANMCO) 2001. Vol. II, Sezione IX (Insufficienza Cardiaca) pag. 1629-1644.
3. Ultrafiltrazione ed emofiltrazione. GC.Marenzi, PG.Agostoni. In: L'insufficienza cardiaca: CD interattivo. SIC 2001, Gruppo di Studio sull'insufficienza cardiaca della Società Italiana di Cardiologia.
4. PG.Agostoni, M.Guazzi, G.Marenzi, MD.Guazzi. Quadri clinici. In: L'insufficienza cardiaca: CD interattivo. SIC 2001, Gruppo di Studio sull'insufficienza cardiaca della Società Italiana di Cardiologia.
5. G.Marenzi, AL. Bartorelli. Effects of chronic kidney disease and contrast-induced nephropathy on prognosis and treatment outcomes of acute coronary syndromes. In: Contrast-Induced Nephropathy, A. Bartorelli & G.Marenzi editors; Taylor & Francis 2006, London and New York, pag. 57-75.
6. G.Marenzi, AL. Bartorelli. Renal replacement therapies. In: Contrast-Induced Nephropathy; A. Bartorelli & G.Marenzi editors; Taylor & Francis 2006, London and New York, pag. 133-148.
7. Marenzi G, Lauri G, Assanelli E. Intermittent hemofiltration for management of fluid overload and administration of contrast media. In: "Critical Care Nephrology", Second Edition. Ronco, Bellomo & Kellum editors. Saunders, Elsevier 2009, Chapter 233:1276-1281.
8. Marenzi G, Bartorelli AL. Contrast-induced nephropathy. In "Peripheral Vascular Intervention", Second Edition. R. Heuser & M. Henry editors. Informa Healthcare 2009, Chapter 93: 799-807.
9. Marenzi G, Bartorelli A. Contrast-induced nephropathy: prognostic implications, prevention and management. In: "Mechanical reperfusion for STEMI: from randomised trials to clinical practice. G. De Luca & A. Lansky editors. Informa Healthcare 2010, Chapter 27.
10. Agostoni P, Marenzi. Ultrafiltration for the treatment of heart failure. In "The Cardiorenal Syndrome". JT. Heywood, JC. Burnett Jr. editors. Cardiotext Publishing 2012, Chapter 11; pag. 159-168.
11. Bartorelli AL, Marenzi G. Contrast agents and renal protection. In: "Percutaneous Interventional Cardiovascular Medicine. The PCR-EAPCI Textbook. Eeckhout E, Serruys PW, Wijns W, Vahanian A, Van Sambeek M, De Palma R, editors. Europa Edition 2012, Part I, Chapter 13:501-527.
12. Marenzi G, Camera M, Banfi C, Colombo G, Brambilla M, Brioschi M, Tremoli E. Chronic kidney disease in acute myocardial infarction: clinical relevance and novel potential fields of investigation. In: "New diagnostic, therapeutic and organizational strategies for acute coronary syndromes patients". Grieco N, Marzegalli M, Paganoni AM, editors. Springer 2013, Part II, pages 123-136.
13. Marenzi G, Lilliu M, Oliva F. I trattamenti sostitutivi renali (CRRT) nell'insufficienza cardiaca acuta e cronica. In: Manuale di Terapia Cardiovascolare, IV edizione A cura di Savonitto S. Il pensiero Scientifico Editore, Capitolo 14 (pag. 485-495).


14. Cosentino N, Marenzi G. La malattia cardiovascolare nel paziente con insufficienza renale. In: Manuale di Terapia Cardiovascolare, IV edizione A cura di Savonitto S. Il pensiero Scientifico Editore, Capitolo 40 (pag. 1125-1144).
15. Marenzi G, Cosentino N, Bartorelli AL. Peri-angiography hemofiltration to reduce portality. In: Reducing Mortality in Acute Kidney Injury. Landoni G, Pisano A, Zangrillo A, Bellomo R, Editors. Springer. Capitolo 8 (pag. 73-80)

Book Edited

1) Contrast-Induced Nephropathy. AL. Bartorelli and G. Marenzi editors. Taylor & Francis 2006, London and New York.

January 16th, 2018

Giancarlo Marenzi

A handwritten signature in black ink, appearing to read 'G. Marenzi', with a large, stylized initial 'G'.